The lipid contract manufacturing market is projected to be worth USD 5.6 billion by 2030, claims Roots Analysis
The rapidly growing demand for lipid drug carriers and excipients, primarily driven by the active development initiatives for COVID-19 vaccines, presents lucrative opportunities for contract service providers having the required capabilities
Every year, a number of potential therapeutic leads fail to clear the clinical evaluation phase and enter the market, owing to poor bioavailability. Lipid nanoparticles and the use of various lipid-based excipients (which improve permeability across biological membranes) have emerged as viable alternatives.
However, owing to several manufacturing related complexities, many contemporary drug developers have demonstrated a preference to rely on CMOs for the supply of GMP grade lipids.
The lipid contract manufacturing market size reaches USD 5.6 billion by 2030, growing at a CAGR of 10%.
Key Market Insights
Around 60 companies claim to offer contract manufacturing services for lipids
The majority (39%) of the industry stakeholders are mid-sized companies, followed by small players (32%) and large / very large firms (29%). In addition, 35% of the CMOs engaged in this domain offer services for liposomes / lipid nanoparticles, followed by those providing services for phospholipids (17%).
Several partnerships were established in this domain, during the period 2016-2021
Acquisitions and manufacturing agreements (23% each) emerged as the most common types of partnership models adopted by stakeholders engaged in this domain. Majority (49%) of the deals were inked for lipid-based FDFs, followed by those signed for lipid-based excipients (30%).
Expansion activity in this domain has grown at a CAGR of ~55%, between 2016 and 2021
Most of such initiatives were focused on the establishment of new facilities (35%) and expanding existing facilities (35%), followed by those carried out for capacity expansion (30%). Further, majority of the investments were made in facilities located in North America (67%) and Europe (28%).
Currently available lipid contract manufacturing capacity is estimated to be over 0.1 million liters
Around 40% of the total capacity is installed for carrying out commercial scale operations. Further, in terms of geography, the maximum lipid contract manufacturing capacity (close to 65%) is installed in North America.
North America and Europe are anticipated to capture close to 70% of the market share, by 2030
In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (11.4%), over the next nine years. Further, in 2030, the majority share (~55%) of contract manufacturing revenues is likely to be generated from projects focused on liposomes / lipid nanoparticles and phospholipids.
Key Questions Answered
§ Who are the leading players engaged in offering lipid contract manufacturing services?
§ Which global regions are considered as key hubs for contract manufacturing of lipid products?
§ Which partnership models are most commonly adopted by stakeholders in this industry?
§ What different expansion initiatives have been undertaken by lipid contract manufacturers?
§ Which factors are likely to influence the decision of whether to carry out lipid manufacturing in-house or outsource these operations?
§ What is current, global lipid manufacturing capacity (in litres) of contract manufacturers?
§ How is the current and future market opportunity likely to be distributed across key market segments?
The USD 5.5+ billion (by 2030) financial opportunity associated with lipid contract manufacturing market has been analyzed across the following segments:
Type of Lipid
§ Liposomes / Lipid Nanoparticles
§ Phospholipids
§ PEGylated lipids
§ Ionizable lipids (Cationic / Anionic)
§ Triglycerides
§ Sphingolipids
§ Neutral lipids
§ Others
Company Size
§ Small
§ Mid-sized
§ Large / Very Large
Scale of Operation
§ Preclinical
§ Clinical
§ Commercial
Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
§ MENA
§ Latin America
§ Rest of the World
The report also features inputs from eminent industry stakeholders, according to whom, a significant proportion of manufacturing operation are presently outsourced. This can be attributed to the fact that most products in this field are specialized formulations and therefore, require advanced expertise. The report includes detailed transcripts of discussions held with the following experts:
§ Asha Van Rooijen (Founder and Chief Executive Officer, Liposoma)
§ Rahul Keswani (Associate Director, Formulation Development, Exelead)
§ John Riley (Director, Process Development-Chemistry, BioVectra) and Clement Mugabe (Acting Manager, Biotech Process Development, BioVectra)
The research includes profiles of key players (listed below), featuring a brief overview of the company, its financial performance (if available), details related to its service portfolio, manufacturing facilities, recent developments and an informed future outlook.
§ Ardena
§ Avanti Polar Lipids
§ CordenPharma
§ Creative Biolabs
§ Evonik
§ Exelead
§ FormuMax Scientific
§ Fresenius Kabi
§ Fujifilm
§ Merck KGaA
§ Nagase Medicals
§ Nippon Fine Chemical
§ T&T Scientific
§ TTY Biopharm
§ VCARE Bio Labs
Contact:
Gaurav Chaudhary
Gaurav.Chaudhary@rootsanalysis.com
